Colorectal cancer (metastatic) - bevacizumab & cetuximab
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
| Guidance type: Technology appraisal |
| Date issued: January 2007 |
We will consult on our review plans for this guidance in May 2009. |
| Reference: TA118 |
SummaryBevacizumab in combination with 5-fluorouracil plus folinic acid, with or without irinotecan, is not recommended for people with metastatic colorectal cancer who have not been treated before. Cetuximab in combination with irinotecan is not recommended for people with metastatic colorectal cancer who have had previous treatment for the cancer that also included irinotecan. Consultants should not stop prescribing bevacizumab or cetuximab for people who were already taking it when the guidance was issued. These patients should be able to carry on taking bevacizumab or cetuximab until they and their consultants decide that it is the right time to stop treatment. |
| Top |
DocumentsFor healthcare professionals
For patients, carers and the public
Background information
|
Implementing this guidanceAny further information NICE has produced to help the NHS implement this guideline locally is linked to below: |
| Top |
